Dr. Baron’s Extensive Life Science Investment Experience and Deep Knowledge of Emerging Growth Pharma and Biotech Markets Will Bolster Outcome’s Client Service Offerings
January 24, 2017, Boston, MA & Reston, VA. Outcome Capital (outcomecapital.wpengine.com), a highly specialized investment banking firm that serves growth companies in the life sciences and technology sectors, strengthened its leadership by adding Ellen S. Baron, Ph.D., to its executive team.
A pharmaceutical and biotechnology veteran, Dr. Baron has more than 30 years of operational, strategic and investment expertise with an emphasis in oncology, neurology, and infectious disease. She joins Outcome from Healthios Capital Markets, LLC, where she was Managing Director, Biopharmaceuticals. There she was responsible for leading the company’s therapeutics practice, orchestrating sophisticated private placements, partnerships and mergers and acquisitions transactions for emerging growth companies. Dr. Baron previously led numerous therapeutic and diagnostic investments as a Partner with Oxford Bioscience Partners, a healthcare venture capital firm. She currently serves on the board of directors of several companies, including Sixth Element Capital, a UK-based oncology focused venture capital fund, and SFH, a Maine-based nutraceutical company. She holds a Ph.D. in Microbiology from Georgetown University School of Medicine and a post-doctorate from New York’s Public Health Research Institute.
“I have committed my 30-year career to working on innovative scientific and business solutions to the most challenging health problems,” said Dr. Baron. “I believe my unique blend of high science and business acumen, coupled with many years of operational, investing and proven deal execution, will deliver new dimensions of service and value for Outcome’s client base.”
Dr. Oded Ben-Joseph, Managing Director at Outcome Capital commented: “This is a strategic hire for Outcome Capital and a central component of our global growth plan. We believe that Ellen will further hone our ability to carve out a clear path to liquidity for our clients as she has been on the front lines of equity financing in the pharmaceutical and biotech segments both in the US and Europe. Ellen brings deep domain expertise across multiple disciplines and will complement Outcome’s entrepreneurial culture.”
About Outcome Capital
Outcome Capital is a unique investment banking firm that provides middle-market growth companies in the life sciences, health care services and technology markets with a value-added client-centric approach to merger, acquisition and corporate finance advisory services. The firm utilizes its proven approach to value enhancement by assisting boards and management teams in navigating both the financial and strategic markets and in implementing the best path for success. Outcome Capital’s strength stems from its unique ability to draw on its wide range of operational, strategic and private equity experience, its expertise across the value chain, and its broad industry relationships. The professionals at Outcome Capital take pride in their ability to help their clients to make well-informed strategic decisions and recognize the full value created by their vision. For more information, visit: http://www.outcomecapital.com.
Outcome Capital Announces ATPCO Has Acquired Routehappy February 26, 2018, Reston, VA and Boston, MA. Outcome Capital, an investment banking firm that serves middle market growth companies in the life science and technology segments, is pleased to announce that ATPCO, the industry-standard data platform for airline industry pricing and shopping data, has acquired Routehappy, the […]Read More
Outcome Capital Announces UCB Pharma Has Acquired Beryllium Discovery June 6, 2017, Boston, MA. Outcome Capital, an investment banking firm that serves middle market growth companies in the life science and technology segments, today announced that UCB Pharma, Ltd. has acquired privately held Beryllium Discovery, LLC. Beryllium, a specialized drug discovery contract research organization (CRO), […]Read More